This has been demonstrated in two randomized phase 3 trials (the SHARP trial and the Asian Pacific trial), which showed that sorafenib, an oral multikinase inhibitor of the serine-threonine kinases Raf-1 and B-Raf and the receptor tyrosine kinase activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor, is effective in treating unresectable HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.